Regulatory Scrutiny Intensifies for Novo Nordisk Over Drug Safety Reporting

FDA mandates corrective action after inspection finds flaws in Novo Nordisk's adverse event reporting for semaglutide drugs Ozempic and Wegovy, amid stock decline.

The U.S. Food and Drug Administration (FDA) has issued a stern warning to Danish pharmaceutical giant Novo Nordisk, alleging significant lapses in the company's safety reporting protocols. This development places the firm under heightened pressure during a period of existing market volatility.

FDA Inspection Uncovers Reporting Deficiencies

A recent inspection conducted by the FDA at Novo Nordisk's U.S. headquarters in early 2025 revealed critical shortcomings. Regulators found that adverse event reports for the blockbuster drug semaglutid—marketed under the brand names Ozempic and Wegovy—were improperly documented. These reports included serious health outcomes, such as strokes and fatalities, linked to the medication.

As a direct consequence of these findings, the agency has mandated that Novo Nordisk submit a comprehensive corrective action plan within 15 business days. The plan must detail how the company intends to resolve the identified flaws in its pharmacovigilance systems.

Company Response and Market Impact

In a bid to contain the fallout, Novo Nordisk's management has emphasized its ongoing efforts to enhance internal reporting procedures, stating that this work began immediately after the inspection last year. The company also asserted that the FDA's communication should not be interpreted as a challenge to the fundamental safety or quality profile of its drugs.

Nevertheless, the news arrives at an inopportune moment for shareholders. The company's stock closed at 33.35 euros on Friday, reflecting a loss of more than half its value over the preceding twelve-month period.

Broader Implications for the Weight-Loss Drug Sector

This incident highlights the increasing regulatory focus on high-profile weight-management pharmaceuticals. To avert potential sanctions in the crucial U.S. market, Novo Nordisk must now demonstrate timely remediation and complete transparency in its handling of patient safety data. The situation underscores the rigorous compliance standards demanded of market leaders in this therapeutic category.